- Home
- BMO vs VRTX Comparison
BMO vs VRTX Comparison
Compare BMO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMO
- VRTX
- Stock Information
- Founded
- BMO 1817
- VRTX 1989
- Country
- BMO Canada
- VRTX United States
- Employees
- BMO N/A
- VRTX N/A
- Industry
- BMO Commercial Banks
- VRTX EDP Services
- Sector
- BMO Finance
- VRTX Technology
- Exchange
- BMO Nasdaq
- VRTX Nasdaq
- Market Cap
- BMO 93.6B
- VRTX 96.6B
- IPO Year
- BMO N/A
- VRTX 1991
- Fundamental
- Price
- BMO $124.61
- VRTX $425.78
- Analyst Decision
- BMO Hold
- VRTX Buy
- Analyst Count
- BMO 1
- VRTX 26
- Target Price
- BMO $163.00
- VRTX $491.78
- AVG Volume (30 Days)
- BMO 709.1K
- VRTX 1.3M
- Earning Date
- BMO 12-04-2025
- VRTX 11-03-2025
- Dividend Yield
- BMO 3.69%
- VRTX N/A
- EPS Growth
- BMO 30.29
- VRTX N/A
- EPS
- BMO 8.24
- VRTX 14.07
- Revenue
- BMO $22,764,550,743.00
- VRTX $11,418,800,000.00
- Revenue This Year
- BMO $24.92
- VRTX $10.93
- Revenue Next Year
- BMO $3.09
- VRTX $9.55
- P/E Ratio
- BMO $15.14
- VRTX $30.28
- Revenue Growth
- BMO 6.89
- VRTX 10.46
- 52 Week Low
- BMO $85.40
- VRTX $362.50
- 52 Week High
- BMO $131.37
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- BMO 44.35
- VRTX 61.49
- Support Level
- BMO $122.83
- VRTX $415.00
- Resistance Level
- BMO $127.82
- VRTX $422.98
- Average True Range (ATR)
- BMO 1.65
- VRTX 8.31
- MACD
- BMO -0.44
- VRTX 0.15
- Stochastic Oscillator
- BMO 27.47
- VRTX 74.36
About BMO Bank Of Montreal
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.